Fair Value Please, page-216

I think what maligold said is pretty consistent with the announcement. It’s also clear from the announcement that at least one other party has been looking, there has been speculation of at least one HK/Chinese group, but they would have been more an acquiring investor rather than someone to push the tech forward and integrate with existing operations, as would be case with sumi and Fuji.

Re it’s just an INBO from sumi, sumi know what they’re doing in this space with the only stem cell Nobel laureate directing them, an INBO from them is much more significant than perhaps any other group globally...but still I agree business as usual and hopefully we’re continuing to move forward with GVHD, CLI, OA and perhaps others eg diabetic wounds with the CRC we’re working with.